Skip to main content
SpringerLink
Log in

From an Identified Risk to Regulatory Measures: Implementation of HLA-B★5701 Screening Before Abacavir Treatment

  • Abstract
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mallal S, et al. Lancet 2002; 359: 727–32

    Article  PubMed  CAS  Google Scholar 

  2. Hetherington S, et al. Lancet 2002; 359: 1121–2

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Afssaps, France

    N. Cachin & C. Kreft-Jais

Authors
  1. N. Cachin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Kreft-Jais
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cachin, N., Kreft-Jais, C. From an Identified Risk to Regulatory Measures: Implementation of HLA-B★5701 Screening Before Abacavir Treatment. Drug-Safety 31, 885 (2008). https://doi.org/10.2165/00002018-200831100-00046

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831100-00046

Keywords

Search

Navigation